Contrasting Ardent Health (NYSE:ARDT) & Q Biomed (OTCMKTS:QBIO)

Q Biomed (OTCMKTS:QBIO) and Ardent Health (NYSE:ARDT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Earnings and Valuation

This table compares Q Biomed and Ardent Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q Biomed	N/A	N/A	N/A	($0.02)	N/A
Ardent Health	$6.32 billion	0.24	$135.81 million	$0.55	19.91

Ardent Health has higher revenue and earnings than Q Biomed. Q Biomed is trading at a lower price-to-earnings ratio than Ardent Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Q Biomed and Ardent Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q Biomed	N/A	N/A	N/A
Ardent Health	1.22%	10.35%	3.36%

Analyst Ratings

This is a summary of current ratings and target prices for Q Biomed and Ardent Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q Biomed	0	0	0	0	0.00
Ardent Health	3	4	7	0	2.29

Ardent Health has a consensus price target of $13.05, indicating a potential upside of 19.14%. Given Ardent Health’s stronger consensus rating and higher probable upside, analysts plainly believe Ardent Health is more favorable than Q Biomed.

Volatility & Risk

Q Biomed has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, Ardent Health has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Summary

Ardent Health beats Q Biomed on 8 of the 9 factors compared between the two stocks.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About Ardent Health

Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.